Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to mediarelations@mycovia.com.

04.27.2020

Susan McGaurn, Pharm.D. to Lead Medical Affairs Strategy as Company Advances Late-Stage Research of Oteseconazole (VT-1161), Aiming to Be the First FDA-Approved Treatment for Recurrent Vulvovaginal Candidiasis

Download PDF

02.11.2020

Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis

Download PDF

12.18.2019

Mycovia Pharmaceuticals Completes Enrollment in its Third Phase 3 Clinical Trial for VT-1161 (ultraVIOLET) in Patients with Recurrent Vulvovaginal Candidiasis

Download PDF

11.12.2019

Mycovia Pharmaceuticals Announces Early Completion of Enrollment for Global Phase 3 Clinical Trials for VT-1161 (VIOLET) for the Treatment of Recurrent Vulvovaginal Candidiasis

Download PDF

11.07.2019

Mycovia Pharmaceuticals to Participate in Women’s Health Panel at BIO-Europe 2019

Download PDF
Transforming healthcare together Careers at Mycovia
Working together to transform healthcare Contact Us